Bleeding News and Research

RSS

Suffering from fatigue, abdominal discomfort or bloody diarrhea? Your doctor might not recommend an uncomfortable endoscopy

People living with fatigue, abdominal discomfort and bloody diarrhea caused by the chronic inflammation of ulcerative colitis may no longer need to undergo frequent and uncomfortable endoscopies, a new study shows.

3 Feb 2005

Drug reviparin reduces the risk of death after heart attack

The drug reviparin (a low molecular weight heparin anticoagulant), when administered to patients with a heart attack, is effective in reducing the risk of death and the risk of a subsequent heart attack, according to a study in the January 26 issue of JAMA.

26 Jan 2005

Use of anti-inflammatory steroids for traumatic head injuries may actually increase the risk of death

The common use of anti-inflammatory steroids for traumatic head injuries like those from car crashes may actually increase the risk of death, according to a new review of studies about the treatment.

24 Jan 2005

RU-486 plus prostaglandins remains the most effective nonsurgical abortion method

The most common medical approach to terminating early pregnancy — the drug RU-486 plus prostaglandins — remains the most effective nonsurgical abortion method, according to a new research review.

24 Jan 2005

Invasive procedures do not necessarily improve survival for heart patients

Invasive procedures, often given to patients as soon as they are admitted to hospital with a life-threatening heart condition, do not necessarily improve survival, finds a study published on bmj.com today.

20 Jan 2005

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.

20 Jan 2005

Clopidogrel (Plavix®) responses appear normal in largest data set

Although individual patients respond differently to treatment with the anti-platelet medication clopidogrel (brand name Plavix®), those variations appear normal and may not indicate important differences in the effectiveness of treatment, according to a new study (PDF file) in the Jan. 18, 2005 issue of the Journal of the American College of Cardiology.

19 Jan 2005

A little anxiety can be a good thing when it comes to cancer symptoms

A little anxiety can be a good thing when it comes to cancer symptoms according to researchers at Washington University School of Medicine in St. Louis. They report that people with low overall anxiety levels were more apt to ignore symptoms of rectal cancer for long periods of time, thereby delaying treatment.

12 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

New hope for millions of patients suffering from liver damage (cirrhosis)

Millions of patients suffering from liver damage (cirrhosis) and failure may benefit from research by the Universities of Edinburgh and Southampton which may lead to new life-saving treatments. There is currently no cure for liver cirrhosis and a patient's only hope of survival is to receive a liver transplant.

5 Jan 2005

Angioplasty may replace bypass for more patients who are also receiving a new heart valve

The death rate during combination surgery to bypass clogged coronary arteries and simultaneously replace a heart valve in very sick patients can be as high as one in five, but a review of records of very sick patients who underwent balloon angioplasty, followed by heart valve replacement surgery, found only one death among 26 patients.

4 Jan 2005

Chronic users NSAIDs have greater risk of bleeding and visible damage to their small intestine

According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, chronic users of non-steroidal anti-inflammatory drugs (NSAIDs) have an increased risk of bleeding and visible damage to their small intestine.

4 Jan 2005

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

First assessment tool to evaluate Quebec Platelet Disorder (QPD)

Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.

22 Dec 2004

Advice for patients who have been taking Celebrex or Bextra

The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Dermatologists recommend adding an E to the ABCD acronym for recognizing early melanomas

One more letter should be added to the alphabetic list of warning signs of melanoma, a potentially deadly skin cancer, according to a group of NYU School of Medicine dermatologists and their Australian colleagues.

8 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004